Top
image credit: Adobe Stock

FDA Approves Cord Blood Stem Cell Product, Omisirge, for Blood Cancer Patients

April 24, 2023

Via: Drugs.com

The U.S. Food and Drug Administration approved Omisirge (omidubicel-onlv), a substantially modified allogeneic cord blood-based cell therapy, to cut the risk of infection in patients with blood cancer following a myeloablative treatment, such as radiation or chemotherapy.

Omisirge is administered as a single, patient-specific intravenous dose for blood cancer patients ≥12 years to hasten recovery of neutrophils. The treatment is composed of human donor stem cells from umbilical cord blood that are processed and cultured with nicotinamide.

Read More on Drugs.com